We have a global team of scientific and medical advisors
who are leaders in their fields
CytImmune has recruited scientific and medical leaders from the US, Europe and Japan to advise the company in key areas including nano-particle design, conjugation chemistry, immunology, cancer biology, clinical design, and pharmaceutical product development. Our advisors include a mix of individuals with deep academic and industry experience.
Kouji Matsushima, PhD
Professor Matsushima currently leads an immunology lab at the Tokyo University of Sciences, Organization for Research Advancement, Research Institute for Biomedical Sciences. Prior to this, he was a professor and leader of an inflammatory immunology lab in the Department of Molecular Preventive Medicine at The University of Tokyo.
In 2017, Dr. Matsushima was the President, International Cytokine Society. In 2019, he was awarded the lifetime achievement award in recognition of his previous work in this field.
Dr. Matsushima’s has advised CytImmune for several years and has had a profound influence on the direction of the company’s technology. His laboratory is evaluating IO+ therapeutics in preclinical studies with existing immunotherapies.
Steven Libutti, MD
Dr. Libutti is Board certified surgical oncologist who has received multiple honors as one of the top oncologists in New York and in the United States. He is currently the Director of the Rutgers Cancer Institute of New Jersey and Vice Chancellor for Cancer Programs, Rutgers Biomedical and Health Sciences. Prior to taking this role, Dr. Libutti was the Director of the Montifiore-Einstein Cancer Center in the Bronx, NY. He began his career as surgeon as a staff surgeon at the NCI and quickly rose to the level of Branch Chief.
Dr. Libutti is researcher as well as a professor and practicing oncologist. His research has focused on tumor neovascular formation and the interaction between tumor cells, endothelial cells and the components of the tumor microenvironment.
Dr. Libutti was the lead investigator for Cytimmune’s phase 1 clinical trial at the NCI. He continues to advise the company on our scientific endeavors and clinical strategies.
Alexander Eggermont, MD
Dr. Eggermont is an oncologist, surgeon and researcher. From 1988 to 2011 Dr. Eggermont was chief surgeon at the Daniel den Hoed cancer center, and from 1994 to 2011 head of the laboratory for experimental surgery there. From 2000 to 2011 he was head of the department for oncological surgery at the Erasmus University, from 2003 to 2016 he was professor for surgical oncology. From 2010 to 2019/2020 Eggermont was director of the Gustave Roussy Institute in Villejuif near Paris and from 2012 to 2020 he was a professor of oncology at the University of Paris-South. Eggermont has been the successor to Hans Clevers as Chief Scientific Officer (CSO) of the Princess Máxima Center for Pediatric Oncology in Utrecht since October 2019.
Eggermont is a managing editor of the European Journal of Cancer, and he is the author or co-author of over 900 scientific publications.
Dr. Eggermont is considered a pioneer in the field of tumor immunology and is well known for his work with high-dose TNF alpha in the highly successful Isolated Limb Perfusion surgical procedure. He advises on CytImmune on our scientific and clinical strategies.
David Kingston, PhD
Professor Kingston recently retired from Virginia Tech where he held multiple positions including Distinguished Professor, Dept of Chemistry and Director, Virginia Tech Center for Drug Discovery. His laboratory focused on the biology and chemistry of small molecules including creating multiple analogues of common chemotherapy drugs such as paclitaxel and doxorubicin.
Dr. Kingston worked with CytImmune to design and deploy the small molecule bind and release chemistries that enable IO+ therapeutics to deliver high doses of small molecule therapies systemically into solid tumors with few or no side effects.
Stanley R. Frankel, MD FACP
`
Since 2009, Dr. Frankel has served as an Adjunct Associate Professor of Medicine in the Division of Hematology/Oncology at Columbia University Vagelos College of Physicians and Surgeons in New York. He has had prior academic appointments at Memorial Sloan Kettering Cancer Center, Roswell Park Cancer Institute, Georgetown University Lombardi Cancer Center and the Greenebaum Cancer Center at the University of Maryland.
Dr. Frankel is a non-executive director at Precision Biosciences and serves on multiple scientific advisory boards, including Adagene, Immunai, and Sutro Biopharma.
Jeffrey Ecsedy, PhD
Jeff is currently the Chief Scientific Officer for Boston based Ikena Oncology, where he leads the teams responsible for discovery, non-clinical, translational sciences and technical operations. Dr. Ecsedy has dedicated his career to research the molecular and cellular events that underlie tumor initiation and progression, and has leveraged that knowledge towards the development of new cancer therapeutic agents. His experience spans early discovery research through continued exploration of approved therapies.
Before joining Ikena Oncology, Dr. Ecsedy was SVP of Research and Development at Kyn Therapeutics, and Head of Oncology Translational Medicine at Takeda Pharmaceuticals, where he oversaw research for the oncology pipeline, supporting programs ranging from the preIND stage through marketed products.
Dr. Ecsedy is widely published, with multiple papers, book chapters and patents to his name; he has also received multiple awards for his work.
Anthony Manning, PhD
In his role as Chief Scientific Officer at Momenta Pharmaceuticals, which was recently acquired by Johnson & Johnson, Anthony Manning, PhD, was responsible for creating and implementing the company’s Novel Drugs Strategy resulting in the discovery and development of four novel autoimmune product candidates. His broad industry experience has also included leadership roles at Aileron Therapeutics, Biogen, Roche Pharmaceuticals, Pharmacia Corporation, and Signal Pharmaceuticals.
A sought-after advisor, Dr. Manning serves on the Board of Directors at Palatin Technologies, and is a co-founder and board chair at the Institute for Biomedical Entrepreneurship, committed to accelerating biomedical innovation. At Harvard Medical School, he is a Scientific Advisor to the Therapeutics Initiative, and a member of the advisory committee to the Blatavatnik Biomedical Accelerator.